Benjamin F. Edwards & Company, Inc. 10x Genomics, Inc. Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in 10x Genomics, Inc. stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 44,785 shares of TXG stock, worth $451,880. This represents 0.02% of its overall portfolio holdings.
Number of Shares
44,785
Previous 438
10124.89%
Holding current value
$451,880
Previous $16,000
5343.75%
% of portfolio
0.02%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding TXG
# of Institutions
304Shares Held
109MCall Options Held
228KPut Options Held
157K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.8MShares$130 Million1.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.1MShares$112 Million0.0% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL7.1MShares$71.7 Million0.02% of portfolio
-
Black Rock Inc. New York, NY6.39MShares$64.5 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.38MShares$54.3 Million0.03% of portfolio
About 10x Genomics, Inc.
- Ticker TXG
- Exchange NASDAQ
- Sector Healthcare
- Industry Health Information Services
- Shares Outstandng 95,046,400
- Market Cap $959M
- Description
- 10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumabl...